{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:28:59Z","timestamp":1773296939341,"version":"3.50.1"},"reference-count":52,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2016,12,13]],"date-time":"2016-12-13T00:00:00Z","timestamp":1481587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The CRISPR\/Cas9 Genome-editing system has revealed promising potential for generating gene mutation, deletion, and correction in human cells. Application of this powerful tool in Fabry disease (FD), however, still needs to be explored. Enzyme replacement therapy (ERT), a regular administration of recombinant human \u03b1 Gal A (rh\u03b1-GLA), is a currently available and effective treatment to clear the accumulated Gb3 in FD patients. However, the short half-life of rh\u03b1-GLA in human body limits its application. Moreover, lack of an appropriate in vitro disease model restricted the high-throughput screening of drugs for improving ERT efficacy. Therefore, it is worth establishing a large-expanded in vitro FD model for screening potential candidates, which can enhance and prolong ERT potency. Using CRISPR\/Cas9-mediated gene knockout of GLA in HEK-293T cells, we generated GLA-null cells to investigate rh\u03b1-GLA cellular pharmacokinetics. The half-life of administrated rh\u03b1-GLA was around 24 h in GLA-null cells; co-administration of proteasome inhibitor MG132 and rh\u03b1-GLA significantly restored the GLA enzyme activity by two-fold compared with rh\u03b1-GLA alone. Furthermore, co-treatment of rh\u03b1-GLA\/MG132 in patient-derived fibroblasts increased Gb3 clearance by 30%, compared with rh\u03b1-GLA treatment alone. Collectively, the CRISPR\/Cas9-mediated GLA-knockout HEK-293T cells provide an in vitro FD model for evaluating the intracellular pharmacokinetics of the rh\u03b1-GLA as well as for screening candidates to prolong rh\u03b1-GLA potency. Using this model, we demonstrated that MG132 prolongs rh\u03b1-GLA half-life and enhanced Gb3 clearance, shedding light on the direction of enhancing ERT efficacy in FD treatment.<\/jats:p>","DOI":"10.3390\/ijms17122089","type":"journal-article","created":{"date-parts":[[2016,12,13]],"date-time":"2016-12-13T10:15:52Z","timestamp":1481624152000},"page":"2089","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Using CRISPR\/Cas9-Mediated GLA Gene Knockout as an In Vitro Drug Screening Model for Fabry Disease"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3295-1938","authenticated-orcid":false,"given":"Hui-Yung","family":"Song","sequence":"first","affiliation":[{"name":"Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huai-Chih","family":"Chiang","sequence":"additional","affiliation":[{"name":"Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Lien","family":"Tseng","sequence":"additional","affiliation":[{"name":"Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chian-Shiu","family":"Chien","sequence":"additional","affiliation":[{"name":"Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsin-Bang","family":"Leu","sequence":"additional","affiliation":[{"name":"Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan"},{"name":"School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan"},{"name":"Division of Cardiology &amp; Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Ping","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4060-9131","authenticated-orcid":false,"given":"Mong-Lien","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuh-Jyh","family":"Jong","sequence":"additional","affiliation":[{"name":"Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80708, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung-Hsuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Genomics Research Center, Academia Sinica, Taipei 11574, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Chung","family":"Yu","sequence":"additional","affiliation":[{"name":"School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan"},{"name":"Division of Cardiology &amp; Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Hwa","family":"Chiou","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan"},{"name":"Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan"},{"name":"School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan"},{"name":"Institute of Clinical Medicine, National Yang-Ming University, Taipei 11221, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2016,12,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ndt\/11.supp7.4","article-title":"Report on management of renale failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry","volume":"11","author":"Tsakiris","year":"1996","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000060184","article-title":"Fabry disease (\u03b1-galactosidase A deficiency): Renal involvement and enzyme replacement therapy","volume":"136","author":"Desnick","year":"2001","journal-title":"Contrib. Nephrol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","article-title":"Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry","volume":"64","author":"Hopkin","year":"2008","journal-title":"Pediatr. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A phase 1\/2 clinical trial of enzyme replacement in fabry disease: Pharmacokinetic, substrate clearance, and safety studies","volume":"68","author":"Eng","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: A randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1750-1172-6-42","article-title":"Pricing and reimbursement of orphan drugs: The need for more transparency","volume":"6","author":"Simoens","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2008.10.004","article-title":"A retrospective analysis of the potential impact of IgG antibodies to agalsidase \u03b2 on efficacy during enzyme replacement therapy for Fabry disease","volume":"96","author":"Benichou","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2183\/pjab.88.18","article-title":"Pharmacological chaperone therapy for Fabry disease","volume":"88","author":"Ishii","year":"2012","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.braindev.2012.12.002","article-title":"Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease","volume":"35","author":"Suzuki","year":"2013","journal-title":"Brain Dev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/adt.2011.0370","article-title":"Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders","volume":"9","author":"Valenzano","year":"2011","journal-title":"Assay Drug Dev. Technol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1042\/BJ20070479","article-title":"Mutant \u03b1-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: Biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin","volume":"406","author":"Ishii","year":"2007","journal-title":"Biochem. J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3858\/emm.2009.41.1.001","article-title":"Effects of a chemical chaperone on genetic mutations in \u03b1-galactosidase A in Korean patients with Fabry disease","volume":"41","author":"Park","year":"2009","journal-title":"Exp. Mol. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1021\/cb500143h","article-title":"Molecular basis of 1-deoxygalactonojirimycin arylthiourea binding to human \u03b1-galactosidase A: Pharmacological chaperoning efficacy on Fabry disease mutants","volume":"9","author":"Yu","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/4801","article-title":"Accelerated transport and maturation of lysosomal \u03b1-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor","volume":"5","author":"Fan","year":"1999","journal-title":"Nat. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.bbadis.2008.03.001","article-title":"Rescue of mutant \u03b1-galactosidase A in the endoplasmic reticulum by 1-deoxygalactonojirimycin leads to trafficking to lysosomes","volume":"1782","author":"Hamanaka","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ymgme.2008.12.017","article-title":"Molecular interaction of imino sugars with human \u03b1-galactosidase: Insight into the mechanism of complex formation and pharmacological chaperone action in Fabry disease","volume":"96","author":"Sugawara","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/mt.2011.271","article-title":"Co-administration with the pharmacological chaperone AT1001 increases recombinant human \u03b1-galactosidase A tissue uptake and improves substrate reduction in Fabry mice","volume":"20","author":"Benjamin","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/mt.2015.87","article-title":"Coformulation of a novel human \u03b1-galactosidase a with the pharmacological chaperone AT1001 leads to improved substrate reduction in fabry mice","volume":"23","author":"Xu","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1073\/pnas.94.6.2540","article-title":"\u03b1-Galactosidase A deficient mice: A model of Fabry disease","volume":"94","author":"Ohshima","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s10545-011-9424-3","article-title":"Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant \u03b1-galactosidase A in cultured fibroblasts from patients with Fabry disease","volume":"35","author":"Porto","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1038\/nprot.2013.132","article-title":"CRISPR interference (CRISPRi) for sequence-specific control of gene expression","volume":"8","author":"Larson","year":"2013","journal-title":"Nat. Protoc."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2013.02.022","article-title":"Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression","volume":"152","author":"Qi","year":"2013","journal-title":"Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/glycob\/cwg034","article-title":"A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease","volume":"13","author":"Lee","year":"2003","journal-title":"Glycobiology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"589","DOI":"10.4161\/auto.6.5.11943","article-title":"Autophagosome maturation is impaired in Fabry disease","volume":"6","author":"Chevrier","year":"2010","journal-title":"Autophagy"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/sj.leu.2402417","article-title":"Cohen, The proteasome: A novel target for cancer chemotherapy","volume":"16","author":"Almond","year":"2002","journal-title":"Leukemia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCGENETICS.109.862920","article-title":"High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population","volume":"2","author":"Lin","year":"2009","journal-title":"Circ. Cardiovasc. Genet."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/humu.21074","article-title":"Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A)","volume":"30","author":"Hwu","year":"2009","journal-title":"Hum. Mutat."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"780","DOI":"10.2119\/molmed.2012.00002","article-title":"Fabry disease: Incidence of the common later-onset \u03b1-galactosidase A IVS4+919G\u2192A mutation in Taiwanese newborns\u2014Superiority of DNA-based to enzyme-based newborn screening for common mutations","volume":"18","author":"Chien","year":"2012","journal-title":"Mol. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"28614","DOI":"10.3390\/ijms161226119","article-title":"Induced pluripotency and gene editing in disease modelling: Perspectives and challenges","volume":"16","author":"Seah","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1517\/17460441.2015.1078788","article-title":"Recent progress in the use of zebrafish for novel cardiac drug discovery","volume":"10","author":"Kessler","year":"2015","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"F1015","DOI":"10.1152\/ajprenal.00283.2016","article-title":"Characterization and phosphoproteomic analysis of a human immortalized podocyte model of Fabry disease generated using CRISPR\/Cas9 technology","volume":"311","author":"Pereira","year":"2016","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/humu.21530","article-title":"A pharmacogenetic approach to identify mutant forms of \u03b1-galactosidase A that respond to a pharmacological chaperone for Fabry disease","volume":"32","author":"Wu","year":"2011","journal-title":"Hum. Mutat."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1750-1172-7-91","article-title":"Safety and pharmacodynamic effects of a pharmacological chaperone on \u03b1-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: Report from two phase 2 clinical studies","volume":"7","author":"Germain","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ymgme.2013.01.009","article-title":"A Phase 2 study of migalastat hydrochloride in females with Fabry disease: Selection of population, safety and pharmacodynamic effects","volume":"109","author":"Giugliani","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/01.GIM.0000069509.57929.CD","article-title":"Comparative evaluation of \u03b1-galactosidase A infusions for treatment of Fabry disease","volume":"5","author":"Hopkin","year":"2003","journal-title":"Genet. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ymgme.2012.08.003","article-title":"Enzyme replacement therapy in patients with Fabry disease: State of the art and review of the literature","volume":"107","author":"Pisani","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/GIM.0b013e3181f13b75","article-title":"Effects of enzyme replacement therapy in Fabry disease\u2014A comprehensive review of the medical literature","volume":"12","author":"Lidove","year":"2010","journal-title":"Genet. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1750-1172-8-47","article-title":"Long term enzyme replacement therapy for Fabry disease: Effectiveness on kidney, heart and brain","volume":"8","author":"Rombach","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","article-title":"Ten-year outcome of enzyme replacement therapy with agalsidase \u03b2 in patients with Fabry disease","volume":"52","author":"Germain","year":"2015","journal-title":"J. Med. Genet."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/mt.2009.220","article-title":"The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease","volume":"18","author":"Khanna","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1750-1172-6-66","article-title":"Therapy of Fabry disease with pharmacological chaperones: From in silico predictions to in vitro tests","volume":"6","author":"Andreotti","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/8904_2011_49","article-title":"Treatment of human fibroblasts carrying NPC1 missense mutations with MG132 leads to an improvement of intracellular cholesterol trafficking","volume":"2","author":"Zampieri","year":"2012","journal-title":"JIMD Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bbrc.2011.10.038","article-title":"Proteasome inhibitors improve the function of mutant lysosomal \u03b1-glucosidase in fibroblasts from Pompe disease patient carrying c.546G>T mutation","volume":"415","author":"Shimada","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ymgme.2012.07.013","article-title":"The therapeutic potential of pharmacological chaperones and proteosomal inhibitors, Celastrol and MG132 in the treatment of sialidosis","volume":"107","author":"Igdoura","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/mt.2014.224","article-title":"Enzyme enhancers for the treatment of Fabry and Pompe disease","volume":"23","author":"Lukas","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1006\/bbrc.2002.6476","article-title":"Inhibition of the ubiquitin-proteasome pathway induces differential heat-shock protein response in cardiomyocytes and renders early cardiac protection","volume":"291","author":"Stangl","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1167\/iovs.05-0002","article-title":"Upregulation of heat shock protein expression by proteasome inhibition: An antiapoptotic mechanism in the lens","volume":"46","author":"Awasthi","year":"2005","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.cell.2008.06.037","article-title":"Chemical and biological approaches synergize to ameliorate protein-folding diseases","volume":"134","author":"Mu","year":"2008","journal-title":"Cell"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nature08710","article-title":"Hsp70 stabilizes lysosomes and reverts Niemann-Pick disease-associated lysosomal pathology","volume":"463","author":"Kirkegaard","year":"2010","journal-title":"Nature"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1194\/jlr.R048090","article-title":"Lysosomal storage diseases and the heat shock response: Convergences and therapeutic opportunities","volume":"55","author":"Ingemann","year":"2014","journal-title":"J. Lipid Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR\/Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat. Protoc."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/17\/12\/2089\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:28:29Z","timestamp":1760210909000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/17\/12\/2089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,13]]},"references-count":52,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2016,12]]}},"alternative-id":["ijms17122089"],"URL":"https:\/\/doi.org\/10.3390\/ijms17122089","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,13]]}}}